Vanda Pharmaceuticals (NASDAQ:VNDA) Earning Somewhat Positive Media Coverage, Accern Reports

News stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.6589288340424 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of equities analysts have weighed in on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 5th. Oppenheimer reaffirmed a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research note on Thursday, September 14th. Piper Jaffray Companies upped their price target on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, September 14th. Jefferies Group reaffirmed a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Finally, BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $21.50.

Vanda Pharmaceuticals (NASDAQ VNDA) traded down $0.25 during trading hours on Thursday, hitting $13.80. The stock had a trading volume of 317,300 shares, compared to its average volume of 551,302. Vanda Pharmaceuticals has a twelve month low of $11.90 and a twelve month high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.01) EPS. equities research analysts predict that Vanda Pharmaceuticals will post -0.42 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-vanda-pharmaceuticals-vnda-share-price.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply